Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jazz Pharmaceuticals
The trial is an open-label safety and efficacy study of subjects with fibromyalgia who completed either study 06-008 or 06-009. Total duration is up to 40 weeks of trial participation.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject has qualified for and completed either study 06-009 (NCT00423813) or 06-008 (NCT00371137).
Subject is able, in the opinion of the investigator, to take Xyrem® for approximately 9-1/2 months.
You may not be if
Subject terminated early from either study 06-009 or 06-008.
Subject experienced any serious adverse event related to study drug in either study 06-009 or 06-008.
Subject, in the opinion of the investigator, experienced an adverse event in 06-009 or 06-008 that may prevent him/her from safely participating in this study.
Clareo Health | Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.
